Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4

Qiudi Tu; Li Zhao; Xianyun Ye; Jiao Zheng

doi:10.1038/s41598-025-30374-x

December 4, 2025Scientific ReportsOpen Access

Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4

View Full Paper

Ask AI

Bookmark

Share

Key Points

Myocardial injury was notably reduced by inhibiting ATF4, impacting autophagy in uremic conditions.
Key metric includes important modulation of autophagy linked to ATF4 levels post-Astragaloside IV treatment.
Analysis focused on the role of the PI3K pathway in regulating autophagy response to AS-IV treatment.
These findings may highlight potential therapeutic targets for managing uremia-related cardiac dysfunction.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis revealed autophagy inhibition improves myocardial injury in uremia, suggesting ATF4 is a key target.

Abstract

AS-IV ameliorated uremia-associated myocardial injury by suppressing ATF4 expression and regulating cardiomyocyte autophagy. The PI3K pathway may modulate autophagy after treatment with AS-IV.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tu et al. (2025) studied this question.

synapsesocial.com/papers/693624ad4fa91c937236c54f https://doi.org/10.1038/s41598-025-30374-x

View Full Paper

Ask AI

Bookmark

Share

Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading